Evidence map›Paper›PMID 28711389›Full record

ArticleVaccine2017

Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi.

Chrispin Chaguza, Jennifer E Cornick, Cheryl P Andam, Rebecca A Gladstone, Maaike Alaerts, Patrick Musicha, Chikondi Peno, Naor Bar-Zeev, Arox W Kamng'ona, Anmol M Kiran and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Molecular Epidemiology ofInternational journal of molecular sciences · 2025
    Pooled it
  3. Comparative pangenomics ofMicrobial genomics · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antimicrobial resistance inFrontiers in public health · 2023
    Article
  9. Observational
  10. Review
  11. Genomic surveillance of invasiveMicrobial genomics · 2021
    Article
  12. Microbial genomics · 2021
    Article
  13. Article
  14. Antibiotic Susceptibility ofAntibiotics (Basel, Switzerland) · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Early Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Chrispin ChaguzaDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Jennifer E CornickDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Cheryl P AndamDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Rebecca A GladstonePathogen Genomics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Maaike AlaertsDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Patrick MusichaDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Department of Biomedical Sciences, University of Malawi College of Medicine, Blantyre, Malawi.
Chikondi PenoMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Naor Bar-ZeevDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Arox W Kamng'onaDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Department of Biomedical Sciences, University of Malawi College of Medicine, Blantyre, Malawi.
Anmol M KiranDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Chisomo L MsefulaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Department of Biomedical Sciences, University of Malawi College of Medicine, Blantyre, Malawi.
Lesley McGeeRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, USA.
Robert F BreimanHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, USA.
Aras KadiogluDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
Neil FrenchDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Robert S HeydermanMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Division of Infection and Immunity, University College London, London, UK.
William P HanageCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Stephen D BentleyDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Pathogen Genomics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
Dean B EverettDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi. Electronic address: Dean.Everett@liverpool.ac.uk.
University of Liverpool · GBMalawi-Liverpool-Wellcome Trust Clinical Research Programme · MWCenter for Disease Dynamics, Economics & Policy · USCenters for Disease Control and Prevention · USEmory University · USWellcome Sanger Institute · GB

Funding

Medical Research Council MR/R003076/1Wellcome TrustWellcome Trust 084679/Z/08/ZWellcome Trust OPP1023440Wellcome Trust OPP1034556
6 · The paper itself

Abstract

introductionPneumococcal infections cause a high death toll in Sub Saharan Africa (SSA) but the recently rolled out pneumococcal conjugate vaccines (PCV) will reduce the disease burden. To better understand the population impact of these vaccines, comprehensive analysis of large collections of pneumococcal isolates sampled prior to vaccination is required. Here we present a population genomic study of the invasive pneumococcal isolates sampled before the implementation of PCV13 in Malawi. MATERIALS AND

methodsWe retrospectively sampled and whole genome sequenced 585 invasive isolates from 2004 to 2010. We determine the pneumococcal population genetic structure and assessed serotype prevalence, antibiotic resistance rates, and the occurrence of serotype switching.

resultsPopulation structure analysis revealed 22 genetically distinct sequence clusters (SCs), which consisted of closely related isolates. Serotype 1 (ST217), a vaccine-associated serotype in clade SC2, showed highest prevalence (19.3%), and was associated with the highest MDR rate (81.9%) followed by serotype 12F, a non-vaccine serotype in clade SC10 with an MDR rate of 57.9%. Prevalence of serotypes was stable prior to vaccination although there was an increase in the PMEN19 clone, serotype 5 ST289, in clade SC1 in 2010 suggesting a potential undetected local outbreak. Coalescent analysis revealed recent emergence of the SCs and there was evidence of natural capsule switching in the absence of vaccine induced selection pressure. Furthermore, majority of the highly prevalent capsule-switched isolates were associated with acquisition of vaccine-targeted capsules.

conclusionsThis study provides descriptions of capsule-switched serotypes and serotypes with potential to cause serotype replacement post-vaccination such as 12F. Continued surveillance is critical to monitor these serotypes and antibiotic resistance in order to design better infection prevention and control measures such as inclusion of emerging replacement serotypes in future conjugate vaccines.

Indexed as

AdolescentAdultBacterial CapsulesChildChild, PreschoolDrug Resistance, Multiple, BacterialEvolution, MolecularFemaleGenome, BacterialHigh-Throughput Nucleotide SequencingHumansInfantInfant, NewbornMalawiMalePneumococcal Infections13-valent pneumococcal vaccinePneumococcal VaccinesVaccines, ConjugateAntibiotic resistanceCapsule switchingEvolutionPopulation structureStreptococcus pneumoniae

Identifiers

PMID28711389
PMCPMC5571440
OpenAlexW2735841736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.